Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 9/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 6/20 | 0.47 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | PLK1 | P53350 | 2/20 | 0.40 |
| ▸ | BRD1 | O95696 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16974436 | 0.88 | MAPK7 (0.53) | BRD4MAPK7LRRK2DCLK1NUAK1 | |
| SCHEMBL16982789 | 0.82 | LRRK2 (0.67) | BRD4MAPK7LRRK2DCLK1NUAK1 | |
| SCHEMBL16974434 | 0.77 | MAPK7 (0.51) | BRD4MAPK7LRRK2DCLK1NUAK1 | |
| SCHEMBL16982790 | 0.76 | LRRK2 (0.73) | BRD4MAPK7LRRK2DCLK1NUAK1 | |
| SCHEMBL18313616 | 0.76 | MAPK7 (0.65) | BRD4MAPK7LRRK2DCLK1NUAK1 | |
| SCHEMBL18371567 | 0.75 | LRRK2 (0.65) | BRD4MAPK7LRRK2DCLK1NUAK1 | |
| SCHEMBL16974435 | 0.75 | BRD4 (0.68) | BRD4MAPK7LRRK2DCLK1NUAK1 | |
| SCHEMBL16984551 | 0.73 | BRD4 (0.66) | BRD4BRDTPARP1PLK1BRD1 | |
| SCHEMBL24334048 | 0.73 | LRRK2 (0.61) | BRD4MAPK7LRRK2DCLK1BRDT | |
| SCHEMBL17854805 | 0.73 | MAPK7 (0.53) | BRD4MAPK7LRRK2DCLK1NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | BRD4 1/4885MAPK7 2747/4885LRRK2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.